Results 221 to 230 of about 539,134 (347)
Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer
Molecular Oncology, EarlyView.G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren +16 more
wiley +1 more source
Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions [PDF]
, 2010 Xinchao Wang +7 more
openalex +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Molecular Oncology, EarlyView.Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte +10 more
wiley +1 more source
Review 1: Lung transplant-from donor selection to graft preparation. [PDF]
J Anesth, 2020 Jin Z +7 more
europepmc +1 more source
Morphological heterogeneity description enabled early and parallel non-invasive prediction of T-cell proliferation inhibitory potency and growth rate for facilitating donor selection of human mesenchymal stem cells. [PDF]
Inflamm Regen, 2022 Imai Y, Kanie K, Kato R.
europepmc +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Improved safety for young whole blood donors with new selection criteria for total estimated blood volume [PDF]
, 2011 Anne F. Eder +6 more
openalex +1 more source
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source